Table 1 Baseline characteristics stratified by PDQ group
PDQ score 7 (5-9) | PDQ score 16 (13-18) | PDQ score ≥ 19 | p value | |
|---|---|---|---|---|
(n = 66) | (n = 23) | (n = 12) | ||
PDQ score | 7 (5–9) | 16 (13–18) | 21 (20–23) | <.0001 |
Female, n (%) | 45 (68.2) | 20 (87.0) | 31 (91.7) | 0.09 |
Age, years (SD) | 56.1 (14.7) | 54.6 (18.9) | 47.4 (15.6) | 0.22 |
Initiated csDMARD, n (%) | 37 (78.7) | 6 (12.8) | 4 (8.5) | |
Disease duration, months | 15.5 (1–104) | 53 (9–47) | 34.5 (24–149.5) | 0.12 |
Current smoker, n (%) | 11 (16.9) a | 7 (30.4) | 2 (16.7) | 0.39 |
Corticosteroid usage, n (%) | 11 (16.7) | 2 (8.7) | 3 (25.0) | 0.42 |
28 Swollen joint count | 2 (1–7) | 5 (2–8) | 2 (1–4) | 0.09 |
28 Tender joint count | 5 (3–10) | 13 (8–16) | 9.5 (6.5–15) | <.0001 |
Tender point count, 0–18 | 6 (4–14) | 10 (7–16) | 12 (6–14) | 0.02 |
Tender point count ≥11, n (%) | 20 (30.3) | 11 (47.8) | 7 (58.3) | 0.09 |
DAS28 (SD) | 4.2 (1.1) | 5.0 (1.2) | 4.8 (0.7) | 0.007† |
HAQ-DI, 0–3 | 0.75 (0.38–1.25) | 1.13 (0.88–1.75) | 1.63 (1.19–1.88) | 0.0004 |
VAS-fatigue, mm | 53.5 (27–71) | 75 (52–89) | 72.5 (60.5–87) | 0.002 |
VAS-pain, mm | 42 (24–60) | 69 (50–82) | 63 (45.5–80.5) | 0.0003 |
VAS-global health, mm | 56 (32–77) | 73 (46–85) | 78 (61.5–90) | 0.03‡ |
GAD-10 score, 0–50 | 6 (3–10) a | 10 (6–17) | 9 (9–12) | 0.008 |
MDI score, 0–50 | 8 (4–12) a | 11 (6–25) | 13.5 (9–19.5) | 0.01 |
SF-36 PCS, 0–100 | 35 (29–42) | 33 (26–37) | 28 (24–32) | 0.02‡ |
SF-36 MCS, 0–100 | 51 (40–57) | 43 (31–51) | 37 (31–49) | 0.005 |
CRP, mg/mL | 8 (3–15) | 4 (0.5–19) | 3 (0.8–8.5) | 0.13 |
IgM-RF positive, n (%) | 41 (62.1) | 15 (65.2) | 8 (66.7) | 1.0 |
Anti-CCP positive, n (%) | 46 (70) | 15 (65) | 7 (58) | 0.72 |
RAMRIS hand synovitis | 7 (5–10) | 9.5 (7–11) | 7 (6–9) | 0.18 |
RAMRIS hand edema | 5 (1–10) | 9.5 (3–22) | 5 (2–13) | 0.12 |